

SWIXX SIGNS CEE REGIONAL AGREEMENT WITH SEAGEN FOR TUKYSA®

SWIXX ANNOUNCEMENT NO. 36

March 1st, 2021

Baar, Switzerland – Swixx Biopharma AG of Baar, Switzerland announced today the signing of a licensing and distribution contract with Seagen Inc. of Seattle, Washington, USA. Under the agreement, Seagen has appointed Swixx as exclusive distributor to market and promote Tukysa® (tucatinib) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia. Tucatinib is an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is over-expressed in multiple cancers, including breast, colorectal, and gastric cancers. Between 15% and 20% of breast cancers cases worldwide are HER2-positive. European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for TUKYSA (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer in January 2020.

“It is a great pleasure for me to announce this agreement with Seagen,” commented Swixx CEO Jean-Michel Lespinasse. “Candidly, our entire staff is tremendously enthused by the opportunity to launch and bring Tukysa to both the CEE medical community and CEE patients. Tukysa is a medicine representing a significant advancement and promises to bring new hope to many women, their families and loved ones. It is a great privilege for our company to be associated with Seagen, and Tukysa, and we appreciate very much to be selected as its CEE partner. Indeed, this new relationship marks another significant milestone for Swixx – Tukysa substantially broadens Swixx’s oncology portfolio across all our EU countries, and will enable us to further build-out our oncology infrastructure, allowing us to better serve our communities, healthcare providers, government entities and patients.

About Swixx Biopharma AG

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 600 employees and sales exceeding 260M Euros in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com

About Seagen Inc.

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. For more information about Seagen, please visit: www.Seagen.com

Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321